Heron Therapeutics to Report Second Quarter 2025 Financial Results on Monday, August 11, 2025
Heron Therapeutics (NASDAQ: HRTX), a commercial-stage biotechnology company, has scheduled its second quarter 2025 financial results conference call for Monday, August 11, 2025, at 4:30 p.m. ET. The company will discuss Q2 2025 financial performance and recent business highlights during the call.
Participants can access the conference call through a registration link and are encouraged to dial in fifteen minutes before the scheduled start time. A webcast will be available through Heron's Investor Relations website section, with a 60-day replay period following the call.
Heron Therapeutics (NASDAQ: HRTX), un'azienda biotecnologica in fase commerciale, ha programmato la conference call per la presentazione dei risultati finanziari del secondo trimestre 2025 per luned矛 11 agosto 2025 alle 16:30 ET. Durante la chiamata, la societ脿 discuter脿 delle performance finanziarie del Q2 2025 e degli ultimi aggiornamenti aziendali.
I partecipanti potranno accedere alla conference call tramite un link di registrazione e sono invitati a collegarsi quindici minuti prima dell'orario previsto. Sar脿 inoltre disponibile una trasmissione in webcast nella sezione Investor Relations del sito di Heron, con la possibilit脿 di riascolto per 60 giorni dopo la chiamata.
Heron Therapeutics (NASDAQ: HRTX), una empresa biotecnol贸gica en etapa comercial, ha programado su llamada de conferencia para los resultados financieros del segundo trimestre de 2025 para el lunes 11 de agosto de 2025 a las 4:30 p.m. ET. Durante la llamada, la compa帽铆a discutir谩 el desempe帽o financiero del Q2 2025 y los aspectos destacados recientes del negocio.
Los participantes pueden acceder a la llamada de conferencia mediante un enlace de registro y se les recomienda conectarse quince minutos antes de la hora programada. Habr谩 una transmisi贸n web disponible en la secci贸n de Relaciones con Inversionistas del sitio web de Heron, con un per铆odo de repetici贸n de 60 d铆as despu茅s de la llamada.
Heron Therapeutics (NASDAQ: HRTX)電� 靸侅梾 雼硠鞚� 靸濍獏瓿淀暀 須岇偓搿�, 2025雲� 2攵勱赴 鞛 鞁れ爜 旎嵓霟办姢 旖滌潉 2025雲� 8鞗� 11鞚� 鞗旍殧鞚� 鞓ろ泟 4鞁� 30攵�(霃欕秬 鞁滉皠)鞐� 鞓堨爼頃橁碃 鞛堨姷雼堧嫟. 鞚措矆 旖滌棎靹滊姅 2025雲� 2攵勱赴 鞛 靹标臣鞕� 斓滉芳 靷梾 頃橃澊霛检澊韸鸽ゼ 雲检潣頃� 鞓堨爼鞛呺媹雼�.
彀胳劃鞛愲姅 霌彪 毵來伂毳� 韱淀暣 旎嵓霟办姢 旖滌棎 鞝戩啀頃� 靾� 鞛堨溂氅�, 鞓堨爼霅� 鞁滌瀾 鞁滉皠 15攵� 鞝勳棎 鞝戩啀頃� 瓴冹潉 甓岇灔頃╇媹雼�. Heron 韴瀽鞛� 甏�瓿� 鞗轨偓鞚错姼 靹轨厴鞐愳劀 鞗轨簮鞀ろ姼臧� 鞝滉车霅橂┌, 旖� 膦呺 頉� 60鞚缄皠 雼れ嫓 霌ｊ赴 靹滊箘鞀り皜 鞝滉车霅╇媹雼�.
Heron Therapeutics (NASDAQ : HRTX), une entreprise biotechnologique en phase commerciale, a programm茅 sa conf茅rence t茅l茅phonique pour les r茅sultats financiers du deuxi猫me trimestre 2025 le lundi 11 ao没t 2025 脿 16h30 ET. Lors de cet appel, la soci茅t茅 discutera des performances financi猫res du T2 2025 ainsi que des faits marquants r茅cents.
Les participants peuvent acc茅der 脿 la conf茅rence t茅l茅phonique via un lien d'inscription et sont encourag茅s 脿 se connecter quinze minutes avant l'heure pr茅vue. Un webcast sera disponible dans la section Relations Investisseurs du site de Heron, avec une p茅riode de replay de 60 jours apr猫s l'appel.
Heron Therapeutics (NASDAQ: HRTX), ein biotechnologisches Unternehmen in der kommerziellen Phase, hat seine Telefonkonferenz zu den Finanzergebnissen des zweiten Quartals 2025 f眉r Montag, den 11. August 2025, um 16:30 Uhr ET angesetzt. W盲hrend des Calls wird das Unternehmen die Finanzergebnisse des Q2 2025 sowie aktuelle Gesch盲ftshighlights besprechen.
Teilnehmer k枚nnen 眉ber einen Registrierungslink an der Telefonkonferenz teilnehmen und werden gebeten, sich f眉nfzehn Minuten vor Beginn einzuw盲hlen. Ein Webcast wird 眉ber den Investor-Relations-Bereich der Heron-Website verf眉gbar sein, mit einer 60-t盲gigen Wiedergabeoption nach dem Call.
- None.
- None.
The conference call can be accessed by phone by utilizing the following聽聽which will provide participants with dial-in details. To avoid delays, we encourage participants to dial into the conference call fifteen minutes ahead of the scheduled start time. The conference call will also be available via webcast under the Investor Relations section of Heron's website at聽www.herontx.com. An archive of the teleconference and webcast will also be made available on Heron's website for 60 days following the call.
About Heron Therapeutics, Inc.
Heron Therapeutics, Inc.聽is a commercial-stage biotechnology company focused on improving the lives of patients by developing and commercializing therapeutic innovations that improve medical care. Our advanced science, patented technologies, and innovative approach to drug discovery and development have allowed us to create and commercialize a portfolio of products that aim to advance the standard-of-care for acute care and oncology patients. For more information, visit聽.
Forward-looking Statements
This news release contains "forward-looking statements" as defined by the Private Securities Litigation Reform Act of 1995. Heron cautions readers that forward-looking statements are based on management's expectations and assumptions as of the date of this news release and are subject to certain risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include, but are not limited to, risks and uncertainties identified in the Company's filings with the Securities and Exchange Commission. Forward-looking statements reflect our analysis only on their stated date, and Heron takes no obligation to update or revise these statements except as may be required by law.
Investor Relations and Media Contact:
Ira Duarte
Executive Vice President, Chief Financial Officer
Heron Therapeutics, Inc.
[email protected]
858-251-4400
View original content to download multimedia:
SOURCE Heron Therapeutics, Inc.
FAQ
When will Heron Therapeutics (HRTX) report Q2 2025 earnings?
How can investors access Heron Therapeutics' Q2 2025 earnings call?
How long will Heron Therapeutics' Q2 2025 earnings call replay be available?
What topics will be covered in Heron Therapeutics' Q2 2025 earnings call?
